# Novel Drug Approvals at FDA

## Novel Drug Approvals for 2024

1. **Iqirvo**: Approved on June 10, 2024, Iqirvo, containing the active ingredient elafibranor, is indicated for the treatment of primary biliary cholangitis. It is to be used in combination with ursodeoxycholic acid.

2. **Rytelo**: Approved on June 6, 2024, Rytelo, which contains imetelstat, is approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes.

3. **Imdelltra**: On May 16, 2024, Imdelltra was approved. This drug, with the active ingredient tarlatamab-dlle, is used for treating extensive stage small cell lung cancer.

4. **Xolremdi**: Approved on April 26, 2024, Xolremdi contains mavorixafor and is indicated for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis).

5. **Ojemda**: Ojemda, with the active ingredient tovorafenib, was approved on April 23, 2024, for the treatment of relapsed or refractory pediatric low-grade glioma.

6. **Anktiva**: Approved on April 22, 2024, Anktiva contains nogapendekin alfa inbakicept-pmln and is used for treating bladder cancer.

7. **Lumisight**: On April 17, 2024, Lumisight was approved. This drug, with the active ingredient pegulicianine, is used as an optical imaging agent for the detection of cancerous tissue.

8. **Zevtera**: Approved on April 3, 2024, Zevtera contains ceftobiprole medocaril sodium and is used for treating certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia.
